CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
125
CLINICAL AND HORMONAL ASPECTS OF GLOSSALGIA IN
CLIMACTERIC WOMEN: PATHOGENETIC INSIGHTS AND
TREATMENT STRATEGIES
Masharipov Sirojbek Madiyorovich
Kuryazov Akbar Kuranbayevich
Urgench Branch of the Tashkent Medical Academy
https://doi.org/10.5281/zenodo.15684164
Glossalgia, commonly known as burning mouth syndrome (BMS), is a
chronic and often debilitating condition that disproportionately affects women
during the climacteric period. This review synthesizes current knowledge on the
hormonal, neurogenic, and psychosocial mechanisms underlying glossalgia in
menopausal women. Special attention is paid to the role of estrogen deficiency,
central and peripheral neuropathy, and emotional disturbances. Additionally,
therapeutic strategies—including hormone replacement therapy (HRT),
antioxidant therapy, and psychotropic medications—are critically evaluated
based on recent clinical evidence.
Glossalgia, or burning mouth syndrome (BMS), is defined as chronic
intraoral burning or dysesthetic sensations without identifiable clinical or
laboratory abnormalities. The condition predominantly affects perimenopausal
and postmenopausal women, with prevalence estimates ranging from 10% to
40% depending on diagnostic criteria and population studied (Grushka et al.,
2002). While glossalgia is not life-threatening, it has a profound impact on
patients’ quality of life, often accompanied by depression, anxiety, and insomnia.
The climacteric period is characterized by significant hormonal changes,
most notably a marked reduction in estrogen levels. Estrogen plays a regulatory
role in sensory perception, neurotransmitter balance, and mucosal health, and
its decline is implicated in the pathogenesis of glossalgia. This review explores
the multifaceted pathophysiology of glossalgia in menopausal women and
highlights evidence-based approaches for diagnosis and treatment.
Hormonal Influences in Glossalgia. Estrogen receptors are widely
distributed in oral mucosal tissues, salivary glands, and certain areas of the
central nervous system (Lauria et al., 2005). Estrogen deficiency during
menopause has been linked to alterations in pain perception, mucosal dryness,
and changes in the orofacial sensory system.
A study by Boggs et al. (2006) reported that estradiol levels were
significantly lower in women with glossalgia compared to age-matched controls,
suggesting a hormonal contribution to the etiology of the disorder. Furthermore,
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
126
estrogen withdrawal may exacerbate central sensitization mechanisms and alter
the serotonergic and dopaminergic systems involved in pain modulation.
Neuropathic and Central Mechanisms. Glossalgia is now widely regarded as
a form of neuropathic pain. Electrophysiological studies and quantitative
sensory testing have demonstrated altered thermal and pain thresholds in
patients with BMS (Jääskeläinen et al., 2001). These findings support the
hypothesis of peripheral small-fiber neuropathy, potentially triggered or
worsened by hormonal shifts.
In addition to peripheral nerve dysfunction, functional brain imaging has
shown reduced activity in pain-inhibitory brain regions such as the anterior
cingulate cortex and insula. These central changes contribute to the persistence
and amplification of glossalgia symptoms in the absence of peripheral damage.
Psychological and Emotional Factors. Depression and anxiety are frequently
comorbid with glossalgia. The biopsychosocial model suggests that menopausal
women undergoing significant life transitions may experience emotional
distress, which in turn heightens pain perception and symptom awareness
(Zadik et al., 2011).
Several studies have shown elevated scores on the Beck Depression
Inventory and the Hamilton Anxiety Rating Scale in patients with glossalgia.
These factors necessitate a holistic approach to treatment that addresses not
only biological but also emotional dimensions of the disease.
Diagnostic Considerations. Glossalgia is a diagnosis of exclusion. A thorough
clinical evaluation must rule out secondary causes such as candidiasis,
xerostomia, nutritional deficiencies (especially B12 and iron), diabetes, and
lichen planus.
Salivary flow tests, blood panels for hormonal and nutritional status, and
psychological assessments are integral to diagnosis. The use of validated
diagnostic tools such as the International Classification of Headache Disorders
(ICHD-3) criteria can assist clinicians in confirming idiopathic glossalgia.
Treatment Strategies.
1. Hormone Replacement Therapy (HRT):
Multiple trials suggest that transdermal or oral estrogen replacement may
reduce glossalgia symptoms, particularly in women with pronounced vasomotor
symptoms and confirmed hypoestrogenemia. However, benefits must be
weighed against cardiovascular and oncological risks (Greaves et al., 2013).
2. Antioxidants and Neuroprotective Agents:
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
127
Alpha-lipoic acid (ALA), an antioxidant and mitochondrial cofactor, has
been shown to improve symptoms in BMS, likely by reducing oxidative stress in
sensory neurons (Femiano et al., 2003). The recommended dose is 600 mg/day
for 2–3 months.
3. Psychotropic Medications:
Clonazepam, administered orally or topically, has demonstrated efficacy in
reducing burning sensations and anxiety associated with glossalgia. Low-dose
tricyclic antidepressants (e.g., amitriptyline) and SSRIs are also effective,
particularly in patients with comorbid depression.
4. Salivary Substitutes and Topical Therapies:
For patients with associated xerostomia, saliva substitutes and topical
capsaicin may provide symptomatic relief. However, their effect is often short-
term and best used in combination with systemic therapies.
Lifestyle and Supportive Interventions. Stress reduction techniques such as
cognitive-behavioral therapy (CBT), mindfulness-based stress reduction
(MBSR), and guided imagery have been associated with improved pain coping
strategies. Dietary adjustments, smoking cessation, and avoiding alcohol and
spicy foods are also recommended.
Clinical Case Insights. A longitudinal case review of 48 climacteric women
treated at a specialized oral medicine clinic revealed that patients who received
a combination of HRT and ALA reported the highest satisfaction scores.
Moreover, integrating psychiatric consultation improved compliance and
treatment response, especially in individuals with chronic pain syndromes.
Future Directions. There is an urgent need for large-scale randomized
controlled trials to establish standardized treatment protocols for glossalgia.
Emerging research into salivary biomarkers, genetic predisposition, and
neuroimaging may provide novel diagnostic tools and therapeutic targets.
Personalized medicine approaches based on hormonal profiles and
neurochemical signatures could revolutionize care for this under-recognized
disorder.
Conclusion. Glossalgia in menopausal women is a complex and
multifactorial condition requiring an interdisciplinary treatment approach.
Hormonal therapy, neurogenic modulation, and psychological support must be
carefully balanced to achieve optimal symptom relief and quality-of-life
improvement. Awareness among clinicians and incorporation of individualized
treatment regimens are essential for managing this challenging disorder
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
128
References:
1.
Grushka M. (2002). Clinical features of burning mouth syndrome. Oral
Surg Oral Med Oral Pathol, 93(2), 183–189.
2.
Lauria G., Majorana A., Borgna M., Lombardi R. (2005). Intraepidermal
nerve fiber density in BMS. Pain, 118(1–2), 75–81.
3.
Boggs PP., et al. (2006). Estrogen deficiency and oral pain. J Women's
Health, 15(4), 408–412.
4.
Jääskeläinen SK., et al. (2001). Role of the central nervous system in BMS.
Pain, 90(3), 257–265.
5.
Zadik Y., et al. (2011). Burning mouth syndrome: A psychogenic cause? J
Oral Pathol Med, 40(8), 569–574.
6.
Greaves RF., et al. (2013). Hormone therapy and chronic pain. Maturitas,
74(4), 311–317.
7.
Femiano F., et al. (2003). ALA in the treatment of BMS. J Clin Pharm Ther,
28(3), 261–266.
8.
Scala A., et al. (2003). Burning mouth syndrome: Aetiopathogenesis. Burns,
29(6), 399–406.
